AR070911A1 - USE OF PARTA RECEPTOR ANTAGONISTS ACTIVATED WITH PROTEASA - Google Patents
USE OF PARTA RECEPTOR ANTAGONISTS ACTIVATED WITH PROTEASAInfo
- Publication number
- AR070911A1 AR070911A1 ARP090100937A ARP090100937A AR070911A1 AR 070911 A1 AR070911 A1 AR 070911A1 AR P090100937 A ARP090100937 A AR P090100937A AR P090100937 A ARP090100937 A AR P090100937A AR 070911 A1 AR070911 A1 AR 070911A1
- Authority
- AR
- Argentina
- Prior art keywords
- pain
- par2
- antagonist
- fracture
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de un antagonista del receptor 2 activado con proteasa (PAR2) para el tratamiento del dolor que incluye el dolor postoperatorio en una incision, el dolor neuropático, el dolor por fractura, el dolor por fractura osteoporotica, el dolor por cáncer de hueso o el dolor articular por gota; el dolor inflamatorio asociado con el síndrome de colon irritable; y la inflamacion relacionada con la artritis reumatoide o la osteoartritis, el antagonista de PAR2 es un anticuerpo anti-PAR2 humano o un fragmento de un anticuerpo que se une al antígeno. Reivindicacion 6: Uso de un antagonista del receptor 2 activado con proteasa (PAR2) segun las reivindicaciones 4 o 5, y uno o varios agentes terapéuticos adicionales seleccionados a partir de otro antagonista de PAR2, un inhibidor de citocina, un fármaco antiepiléptico, un inhibidor de NGF, una colchicina, un fármaco anti-inflamatorio no esteroideo (NSAID), un corticoesteroide y un inhibidor de TNF, en la preparacion de un medicamento para tratar, inhibir o aliviar el dolor asociado con la inflamacion, el dolor postoperatorio en una incision, la neuropatía, la fractura de huesos, la fractura osteoporotica, el cáncer de hueso o la gota.Use of a protease activated receptor 2 (PAR2) antagonist for the treatment of pain that includes postoperative pain in an incision, neuropathic pain, fracture pain, osteoporotic fracture pain, bone cancer pain or joint pain from gout; inflammatory pain associated with irritable bowel syndrome; and inflammation related to rheumatoid arthritis or osteoarthritis, the PAR2 antagonist is a human anti-PAR2 antibody or a fragment of an antibody that binds to the antigen. Claim 6: Use of a protease activated receptor 2 (PAR2) antagonist according to claims 4 or 5, and one or more additional therapeutic agents selected from another PAR2 antagonist, a cytokine inhibitor, an antiepileptic drug, an inhibitor of NGF, a colchicine, a non-steroidal anti-inflammatory drug (NSAID), a corticosteroid and a TNF inhibitor, in the preparation of a medication to treat, inhibit or relieve pain associated with inflammation, postoperative pain in an incision , neuropathy, bone fracture, osteoporotic fracture, bone cancer or gout.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3790808P | 2008-03-19 | 2008-03-19 | |
US11915508P | 2008-12-02 | 2008-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070911A1 true AR070911A1 (en) | 2010-05-12 |
Family
ID=40718925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090100937A AR070911A1 (en) | 2008-03-19 | 2009-03-16 | USE OF PARTA RECEPTOR ANTAGONISTS ACTIVATED WITH PROTEASA |
Country Status (6)
Country | Link |
---|---|
AR (1) | AR070911A1 (en) |
CL (1) | CL2009000660A1 (en) |
PE (1) | PE20091693A1 (en) |
TW (1) | TW201002345A (en) |
UY (1) | UY31723A (en) |
WO (1) | WO2009117481A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7214655B2 (en) * | 2001-05-21 | 2007-05-08 | Johnson & Johnson Consumer Companies, Inc. | Peptides and the use thereof in darkening the skin |
US7888482B2 (en) | 2006-02-10 | 2011-02-15 | Amgen Inc. | Antibodies that bind PAR-2 |
JO3246B1 (en) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | High affinity human antibodies to human protease-activated receptor-2 |
WO2013064583A1 (en) | 2011-11-04 | 2013-05-10 | Lipotec, S.A. | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions |
BR112016006151A2 (en) | 2013-09-25 | 2017-08-01 | Vertex Pharma | imidazopyridazines useful as inhibitors of the par-2 signaling pathway |
US20160000791A1 (en) | 2014-07-07 | 2016-01-07 | Mayo Foundation For Medical Education And Research | Par1 modulation to alter myelination |
CN109152777A (en) * | 2016-05-20 | 2019-01-04 | 武田药品工业株式会社 | The treatment of pain |
WO2017223427A1 (en) * | 2016-06-23 | 2017-12-28 | Mayo Foundation For Medical Education And Research | Par2 modulation to alter myelination |
KR20190129925A (en) * | 2017-03-16 | 2019-11-20 | 메디뮨 리미티드 | Anti-PAR2 Antibodies and Their Uses |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5629174A (en) * | 1993-07-26 | 1997-05-13 | Cor Therapeutics, Inc. | Recombinant C140 receptor |
KR19980701637A (en) * | 1995-01-25 | 1998-06-25 | 찰스 홈시 | Recombinant C14 receptor, its agonist and antagonist, and nucleic acid encoding the receptor |
CA2570389A1 (en) * | 2004-06-17 | 2005-12-29 | Osteologix A/S | Treatments comprising strontium for rheumatic and arthritic diseases and pain |
-
2009
- 2009-03-16 AR ARP090100937A patent/AR070911A1/en unknown
- 2009-03-17 PE PE2009000397A patent/PE20091693A1/en not_active Application Discontinuation
- 2009-03-18 CL CL2009000660A patent/CL2009000660A1/en unknown
- 2009-03-18 TW TW098108692A patent/TW201002345A/en unknown
- 2009-03-18 WO PCT/US2009/037504 patent/WO2009117481A1/en active Application Filing
- 2009-03-19 UY UY0001031723A patent/UY31723A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CL2009000660A1 (en) | 2010-04-16 |
TW201002345A (en) | 2010-01-16 |
PE20091693A1 (en) | 2009-11-16 |
WO2009117481A1 (en) | 2009-09-24 |
UY31723A (en) | 2009-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR070911A1 (en) | USE OF PARTA RECEPTOR ANTAGONISTS ACTIVATED WITH PROTEASA | |
Cao et al. | Pharmacotherapy for knee osteoarthritis: current and emerging therapies | |
Robinson et al. | Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis | |
Oo et al. | The development of disease-modifying therapies for osteoarthritis (DMOADs): the evidence to date | |
Oo et al. | Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics | |
Rosero et al. | Preemptive, preventive, multimodal analgesia: what do they really mean? | |
Bigoni et al. | Acute and late changes in intraarticular cytokine levels following anterior cruciate ligament injury | |
Yang et al. | Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial | |
Adami et al. | Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial | |
Ominsky et al. | Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones | |
Baltzer et al. | Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis | |
CY1123211T1 (en) | METHODS FOR ANTIMETOPY OR PREVENTION OF HMIKPANIA | |
Watt et al. | New drug treatments for osteoarthritis: what is on the horizon? | |
GT200800269A (en) | A NEW VIRULENCE DETERMINED WITHIN THE STRUCTURAL GLYCOPROTEIN E2 OF THE CLASSIC VIRUS OF THE SWINE FEVER | |
AR081434A1 (en) | ANTIBODY OF THE PEPTIDE RELATED TO THE CALCITONINE GENE (CGRP), PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE OF THE ANTIBODY TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT PAIN OR MIGRANE PAIN AND ANOGEN ANOGEN FRAGMENT | |
CY1118044T1 (en) | COMPOSITION PREPARATION WITH COMPETITOR AND CORTICOSTEROIDS | |
Chen et al. | Arthrofibrosis and large joint scarring | |
PE20141563A1 (en) | MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR PATHWAY INHIBITOR | |
EA200900709A1 (en) | METHODS OF TREATMENT OF CHRONIC INFLAMMATORY DISEASES USING AN ANTAGONIST GM-CSF | |
Altman | Pharmacological therapies for osteoarthritis of the hand: a review of the evidence | |
MX362591B (en) | Methods of treating rheumatoid arthritis using il-17 antagonists. | |
AR039656A1 (en) | USE OF ANTI-TNF ALFA AND OTHER PHARMACO ANTIBODIES | |
CL2007003094A1 (en) | DISCONTINUOUS CRYSTALLIZATION METHOD FOR CRYSTALLIZING AN ANTI-FACTOR ANTIBODY OF HUMAN ALPHA TUMOR NECROSIS (TNF ALFA); ANTIBODY CRYSTAL; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; AND ITS USE TO TREAT DISEASES RELATED TO TNF ALFA | |
CY1123240T1 (en) | ANTI-FGF23 ANTIBODY AND A PHARMACEUTICAL COMPOSITION CONTAINING IT | |
Trueba Davalillo et al. | Clinical efficacy of intra-articular injections in knee osteoarthritis: a prospective randomized study comparing hyaluronic acid and betamethasone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |